熱點掃描 | 手遊股盤初跳水拖累大市,醫藥股逆勢衝高
uSMART盈立智投8月3日消息,港股三大指數盤初跳水,恆指跌1.42%,報25865.18點,成交額942.28億,國企指數跌1.63%,恆生科技指數跌2.93%,港股通淨流出34.01億。
手遊股盤初直線跳水,截止10:58,中手遊跌超19%,心動公司、創夢天地跌超14%,禪遊科技跌超13%,網易、嗶哩嗶哩均跌超12%,騰訊跌超9%。經參報今日發文批網絡遊戲,將其比作新型“毒品”,直接點名騰訊《王者榮耀》,並稱“精神鴉片”竟長成數千億產業!“任何一個產業、一項競技都不能以毀掉一代人的方式來發展,處罰的力度要同步跟上”。
資源股下挫,截止10:58,鞍鋼股份跌超5%,贛鋒鋰業、馬鞍山鋼鐵、五礦資源、中國有色礦業均跌超4%,中國鋁業跌超4%,紫金礦業、江西銅業跌超3%。中鋼協此前表示,鋼鐵企業成本上升,盈利空間將受擠壓。中泰證券指出,隨着週五中央再次提出要做好大宗商品保供穩價工作,鋼價上漲存在限制,並可能複製2018年的情景。
芯片股回調,截止10:58,晶門半導體跌超5%,上海復旦、中芯國際跌超3%,ASM太平洋跌超2%,華虹半導體跌超1%。
受手遊股拖累,恆生科技指數下挫,截止10:58,快手、美團跌超5%,快手續刷歷史新低,新東方在線跌近5%,萬國數據跌超4%,微盟跌超3%,阿裏、小米、京東、舜宇均跌超1%,Strategy Analytic稱:小米集團-W歐洲智能手機出貨量份額達25%,位居榜首;百度跌近1%,金蝶國際、海爾智家逆勢上漲超2%。
醫藥股逆勢衝高,截止10:58,復星醫藥漲超5%,開拓藥業漲超4%,康龍化成、國藥控股、石藥集團、四環醫藥漲超2%。近日國內疫情情況愈發嚴重,衛健委公佈,昨日報告新增確診病例90例,其中境外輸入病例29例,本土病例61例。
生物技術亦走強,截止10:58,基石藥業漲超11%,藥監局已受理艾伏尼布的新藥上市申請及擬納入優先評審;康希諾生物、金斯瑞生物均漲9%,此前康希諾霧化吸入新冠疫苗1期臨牀結果發表。君實生物漲超6%,歐康維視漲超4%,昊海生科、藥明康德、泰格醫藥均漲超3%。
個股方面,截止10:58,奈雪的茶跌近9%,食品安全問題遭曝光;南方錳業再漲超7%,部分電解錳現貨出廠價站上24000元/噸;信義光能漲超8%,上半年純利同比增長118.4%至30.72億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.